Scientists at the Fels Cancer Institute for Personalized Medicine and the Department of Cancer and Cell Biology at the Lewis Katz School of Medicine at Temple University and Fox Chase Cancer Center have developed a novel therapeutic strategy that attacks and destroys leukemia clones, an approach that could potentially prevent patients from relapsing after treatment.
